Maitri Health Technologies Corp (MHTCF) fair value: what the stock is really worth
As of Sep 25, 2026: fair value of Maitri Health Technologies Corp $4.46, price $5.55, upside -19.6%, quality 37 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Maitri Health Technologies Corp for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
31‑month range $4.35 – $10.10 · fair‑value band $3.46 – $5.08 · the $5.55 price screens above the $4.46 fair value. Dashed = 300-day average. As of Sep 24, 2026.
Follow Maitri Health Technologies in your weekly email
Every Wednesday you see whether Maitri Health Technologies is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Mitsui High-tec, Inc. produces and sells lead frames, precision tools, motor cores, and surface grinders for the electronics, automobile, and industrial machinery industries in Japan, China, and internationally. It operates through three segments: Molds and Machine Tools, Electronic Components, and Electrical Components.
Show more
Mitsui High-tec, Inc. produces and sells lead frames, precision tools, motor cores, and surface grinders for the electronics, automobile, and industrial machinery industries in Japan, China, and internationally. It operates through three segments: Molds and Machine Tools, Electronic Components, and Electrical Components. The company offers precision tooling/precision parts for motor, leadframes, and other types of tooling products. The company also offers surface grinders; and overhaul and after-sales services. The company was formerly known as Mitsui Mfg. Co., Ltd. and changed its name to Mitsui High-tec, Inc. in May 1984. Mitsui High-tec, Inc. was incorporated in 1934 and is headquartered in Kitakyushu, Japan.
Stock analysis
Maitri Health Technologies Corp (MHTCF) currently trades at $5.55, while our model-based Fair Value estimate is $4.46, 19.6% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Asset-Based group reads highest at a median of $2.65 per share, and 2 of the 14 models we run sit above the $5.55 price.
Bear case: the Earnings-Based group reads lowest at $1.20, and 12 of the 14 models stay below the price. Evidence for this calculation is medium.
Scenario range: $3.46 (bear) to $5.08 (bull), the price of $5.55 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 37/100 (below-average quality), in the Technology sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Maitri Health Technologies Corp reported revenue of ¥218B in FY2025 versus ¥139B in FY2021, a compound +11.9%/yr. Reported net income was ¥3.2B in FY2025, compounding −28.1%/yr from FY2021.
Key figures
Market cap $1.0B · P/E ratio 50.5 · P/S ratio 0.73 · EPS (TTM) $0.1100 · Dividend yield 2.1% · Net margin 1.4% · Return on equity 6.1% · Return on assets (EBIT) 9.4%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (medium confidence).
What moves the price
The share trades about 1% below its 52-week high and 16% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Technology peers we cover trades at −41% fair-value upside, at −20%, MHTCF screens cheaper than that median.
Fair Value models
Bear $3.46Fair Value $4.46Bull $5.08
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.48/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+1.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.5%
Start year 2020 (pandemic)
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in JPY ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in JPY: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−42.2%
Earnings growth per share plus dividend.
Earnings per share, growth per year−44.3%
Dividend (yield on the price)2.1%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.0% → 6%
Compare Maitri Health Technologies Corp with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Semiconductors · 335 stocks
Beats the industry median on 6/13 measures
A mixed picture versus its industry peers.
Valuation
Quality Score37 · Bottom 25%
Fair Value upside−19.6% · Above median
Profitability
Return on equity (TTM)6.1% · Below median
Return on assets3.6% · Above median
Net margin (TTM)3.0% · Below median
Operating margin (TTM)7.2% · Below median
Growth and dividend
Revenue growth13.2% · Below median
Dividend yield (TTM)2.1% · Above median
Balance sheet
Debt / equity0.60× · Highest 25%
Valuation Multiplesvs Semiconductors median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Maitri Health Technologies Corp Fair Value". https://www.fairvalue-calculator.com/stock/MHTCF
Frequently asked questions
Is Maitri Health Technologies Corp (MHTCF) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $4.46 versus a price of $5.55, about −20% upside (overvalued).
What is the fair value of MHTCF?
Our model-based fair value for Maitri Health Technologies Corp is $4.46 (as of Sep 24, 2026), built from audited fundamentals. The current price: $5.55.
What is the quality score of MHTCF?
Maitri Health Technologies Corp has a Quality Score of 37/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Maitri Health Technologies Corp (MHTCF)?
Our model-based price target is the fair value of $4.46 (as of Sep 24, 2026) from 14 valuation models. Cautious scenario $3.46, optimistic scenario $5.08. It is a calculation from audited fundamentals, not an analyst target.
What is the Maitri Health Technologies Corp stock forecast for 2026?
Our models put fair value at $4.46, about −20% upside versus a price of $5.55 (overvalued). Cautious scenario $3.46, optimistic scenario $5.08. The calculation is refreshed regularly with new filings.
What is the revenue of Maitri Health Technologies Corp (MHTCF)?
Maitri Health Technologies Corp reported trailing-twelve-month revenue of about ¥226B (latest available figure, as of Sep 24, 2026).
Does Maitri Health Technologies Corp pay a dividend?
Maitri Health Technologies Corp currently shows a dividend yield of about 2.14% relative to its recent price (as of Sep 24, 2026).
What is the intrinsic value of Maitri Health Technologies Corp (MHTCF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Maitri Health Technologies Corp it is $4.46 per share (as of Sep 24, 2026), against a price of $5.55. It is the blended result of 14 valuation models (cash flow, earnings, asset, dividend).
Is Maitri Health Technologies Corp stock overvalued or undervalued in 2026?
As of Sep 24, 2026, MHTCF trades above its calculated fair value: price $5.55, fair value $4.46, a gap of about −20% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of MHTCF?
No. The price is what the market pays today ($5.55); the fair value is what the company's own numbers justify ($4.46). For Maitri Health Technologies Corp the two are $1.09 per share apart. That gap is exactly why we show both numbers side by side.
How much is Maitri Health Technologies Corp worth?
The market values Maitri Health Technologies Corp at about $1.0B (market capitalisation, as of Sep 24, 2026). Per share that is $5.55; our models calculate a fair value of $4.46 per share.
What do the bullish and bearish scenarios say about MHTCF?
Our models span a range for Maitri Health Technologies Corp: cautious scenario $3.46, base $4.46, optimistic $5.08 per share (as of Sep 24, 2026, price $5.55). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of MHTCF?
Maitri Health Technologies Corp trades at a price-to-earnings ratio of 50.5 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $4.46 is built from several models across several years. Other multiples: P/B 1.4, P/S 0.7, EV/EBITDA 6.7.
How solid is the balance sheet of Maitri Health Technologies Corp (MHTCF)?
Balance-sheet figures for Maitri Health Technologies Corp (as of Sep 24, 2026): return on equity 6.1%, debt of 0.60 per unit of equity. They feed the Quality Score of 37/100, which measures business quality independently of the share price.
How far is MHTCF from its 52-week high?
Maitri Health Technologies Corp trades at $5.55, about 1% below its 52-week high of $5.62 and 16% above the low of $4.77 (as of Sep 25, 2026). Distance from the high says nothing about value: that is what the fair value of $4.46 is for.
Which stocks are comparable to Maitri Health Technologies Corp?
From the same area (Technology) we also value NVIDIA Corporation, Taiwan Semiconductor Manufacturing Company, Broadcom Inc, Micron Technology, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Maitri Health Technologies Corp stock attractive at the current price?
The data as of Sep 24, 2026: price $5.55, calculated fair value $4.46 (−20%), Quality Score 37/100, from 14 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of MHTCF calculated?
We run Maitri Health Technologies Corp through 14 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $4.46, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.9 % above its aggregate fair value. Maitri Health Technologies Corp itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Maitri Health Technologies Corp (MHTCF)?
The closing price on Sep 25, 2026 was $5.55. Our model-based fair value is $4.46, about −20% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Maitri Health Technologies Corp right now?
The price sits above even our optimistic bull case ($5.08). The favourable scenario is already priced in. Weak quality (37/100) and above fair value at the same time, the margin of safety is missing on both counts.
Key figures of Maitri Health Technologies Corp
How large is the market capitalisation of Maitri Health Technologies Corp (MHTCF)?
The market capitalisation of Maitri Health Technologies Corp is $1.0B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Maitri Health Technologies Corp (MHTCF)?
The price-to-sales ratio of Maitri Health Technologies Corp is 0.73 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Maitri Health Technologies Corp (MHTCF)?
Earnings per share at Maitri Health Technologies Corp are $0.1100 (price ÷ EPS = P/E 50.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Maitri Health Technologies Corp (MHTCF)?
The dividend yield of Maitri Health Technologies Corp is 2.1% (payout 108%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Maitri Health Technologies Corp (MHTCF)?
The net margin of Maitri Health Technologies Corp is 1.4% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Maitri Health Technologies Corp (MHTCF)?
The return on equity (ROE) of Maitri Health Technologies Corp is 6.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Maitri Health Technologies Corp (MHTCF)?
On an EBIT basis the return on assets of Maitri Health Technologies Corp is 9.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Maitri Health Technologies Corp (MHTCF)?
The operating margin of Maitri Health Technologies Corp is 7.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Maitri Health Technologies Corp (MHTCF)?
Revenue at Maitri Health Technologies Corp is growing +13.2% versus a year earlier (3y avg +7.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Maitri Health Technologies Corp (MHTCF)?
Earnings per share at Maitri Health Technologies Corp are growing +374% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Maitri Health Technologies Corp (MHTCF) generate?
The free cash flow of Maitri Health Technologies Corp is −¥4.7B (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Maitri Health Technologies Corp (MHTCF) carry?
The net debt of Maitri Health Technologies Corp is ¥40.4B (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Maitri Health Technologies Corp in the live analysis
One click puts Maitri Health Technologies Corp on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Some data
Sep 24, 2026